Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling

IF 5.6 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2025-08-28 Epub Date: 2025-06-14 DOI:10.1016/j.intimp.2025.115046

Xing Wang , Haihua Liu , Huijie Fan , Bingqi Han , Haixin Ye , Xidong Ye , Dingding Zhang , Fopei Ma , Qin Huang , Lifang Cheng , Yang Zhao , Xinge Chen , Jinhao Chen , Leyi Tan , Yutong Jiang , Xiaoshan Zhao , Juan Li , Mukeng Hong

{"title":"Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling","authors":"Xing Wang , Haihua Liu , Huijie Fan , Bingqi Han , Haixin Ye , Xidong Ye , Dingding Zhang , Fopei Ma , Qin Huang , Lifang Cheng , Yang Zhao , Xinge Chen , Jinhao Chen , Leyi Tan , Yutong Jiang , Xiaoshan Zhao , Juan Li , Mukeng Hong","doi":"10.1016/j.intimp.2025.115046","DOIUrl":null,"url":null,"abstract":"<div><div>As crucial roles of interkingdom crosstalk between plants and mammalian, plant-derived vesicle- like nanoparticles (PDVLNs) have various bioactivity and higher penetrability, showing potentiality to develop as therapeutic agents and drug carriers. Here, we isolated nanoparticles from Ginseng, a crucial candidate herbal medicine for rheumatoid arthritis (RA), and found that Ginseng-derived nanoparticles (GDNPs) could spread into joints and exhibited anti-inflammatory effect in collagen-induced arthritis (CIA) mice. Mechanistically, GDNPs delivered ginseng specific pgi-miR6135j into synovial macrophages to directly inhibit KRAS expression, a positive regulator of MAPK pathway, resulting reduced phosphorylation levels of MAPK pathway. Our study reveals the therapeutic mechanism of Ginseng in RA and suggest potential biotherapeutic applications of PDVLNs.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"161 ","pages":"Article 115046"},"PeriodicalIF":5.6000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925010367","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As crucial roles of interkingdom crosstalk between plants and mammalian, plant-derived vesicle- like nanoparticles (PDVLNs) have various bioactivity and higher penetrability, showing potentiality to develop as therapeutic agents and drug carriers. Here, we isolated nanoparticles from Ginseng, a crucial candidate herbal medicine for rheumatoid arthritis (RA), and found that Ginseng-derived nanoparticles (GDNPs) could spread into joints and exhibited anti-inflammatory effect in collagen-induced arthritis (CIA) mice. Mechanistically, GDNPs delivered ginseng specific pgi-miR6135j into synovial macrophages to directly inhibit KRAS expression, a positive regulator of MAPK pathway, resulting reduced phosphorylation levels of MAPK pathway. Our study reveals the therapeutic mechanism of Ginseng in RA and suggest potential biotherapeutic applications of PDVLNs.

查看原文本刊更多论文

人参外泌体miRNA通过介导KRAS-MAPK信号改善类风湿关节炎

植物源性囊泡样纳米颗粒（PDVLNs）具有多种生物活性和较高的穿透性，在植物和哺乳动物之间的界间串扰中起着至关重要的作用，显示出作为治疗药物和药物载体的潜力。本研究从类风湿关节炎（RA）的重要候选草药人参中分离出纳米颗粒，发现人参衍生的纳米颗粒（GDNPs）可以扩散到关节中，并在胶原诱导关节炎（CIA）小鼠中表现出抗炎作用。机制上，GDNPs将人参特异性pgi-miR6135j传递到滑膜巨噬细胞中，直接抑制MAPK通路正调节因子KRAS的表达，导致MAPK通路磷酸化水平降低。我们的研究揭示了人参在RA中的治疗机制，并提出了PDVLNs的潜在生物治疗应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.